ZA200500053B - Method for isolating an intestinal cholesterol binding protein - Google Patents
Method for isolating an intestinal cholesterol binding protein Download PDFInfo
- Publication number
- ZA200500053B ZA200500053B ZA200500053A ZA200500053A ZA200500053B ZA 200500053 B ZA200500053 B ZA 200500053B ZA 200500053 A ZA200500053 A ZA 200500053A ZA 200500053 A ZA200500053 A ZA 200500053A ZA 200500053 B ZA200500053 B ZA 200500053B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- cholesterol
- compound
- biological material
- intestinal
- Prior art date
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 37
- 102000049842 cholesterol binding protein Human genes 0.000 title claims description 3
- 108010011793 cholesterol binding protein Proteins 0.000 title claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 101
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 97
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 44
- 239000003112 inhibitor Substances 0.000 claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 35
- 239000012620 biological material Substances 0.000 claims description 27
- 230000001906 cholesterol absorption Effects 0.000 claims description 23
- 210000000110 microvilli Anatomy 0.000 claims description 21
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010014476 Elevated cholesterol Diseases 0.000 claims description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 6
- 238000002474 experimental method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- -1 2- azetidinone compound Chemical class 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 4
- 108010051423 streptavidin-agarose Proteins 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 21
- 239000007983 Tris buffer Substances 0.000 description 18
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 18
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 102000023732 binding proteins Human genes 0.000 description 14
- 108091008324 binding proteins Proteins 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000005063 solubilization Methods 0.000 description 11
- 230000007928 solubilization Effects 0.000 description 11
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 10
- 102100022749 Aminopeptidase N Human genes 0.000 description 10
- 108010049990 CD13 Antigens Proteins 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 10
- 102400000472 Sucrase Human genes 0.000 description 10
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 235000011073 invertase Nutrition 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 108010052285 Membrane Proteins Proteins 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 229940093499 ethyl acetate Drugs 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000005222 photoaffinity labeling Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 241000724266 Broad bean mottle virus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940113549 Cholesterol inhibitor Drugs 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000011537 solubilization buffer Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102400000471 Isomaltase Human genes 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000001085 differential centrifugation Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- KKBXLTKVWSOEIJ-UHFFFAOYSA-N 1-(4-aminophenyl)-3-(3-hydroxy-3-phenylpropyl)-4-(3-methoxyphenyl)azetidin-2-one Chemical compound COC1=CC=CC(C2N(C(=O)C2CCC(O)C=2C=CC=CC=2)C=2C=CC(N)=CC=2)=C1 KKBXLTKVWSOEIJ-UHFFFAOYSA-N 0.000 description 2
- XUXGBRBAPQCBBG-UHFFFAOYSA-N 1-(4-aminophenyl)-3-[3-[tert-butyl(dimethyl)silyl]oxy-3-phenylpropyl]-4-(3-methoxyphenyl)azetidin-2-one Chemical compound COC1=CC=CC(C2N(C(=O)C2CCC(O[Si](C)(C)C(C)(C)C)C=2C=CC=CC=2)C=2C=CC(N)=CC=2)=C1 XUXGBRBAPQCBBG-UHFFFAOYSA-N 0.000 description 2
- YZJSVLVRDFIMHX-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-(4-nitrophenyl)methanimine Chemical compound C1=CC(OC)=CC=C1C=NC1=CC=C([N+]([O-])=O)C=C1 YZJSVLVRDFIMHX-UHFFFAOYSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- AYZCEVRQUAJWBW-UHFFFAOYSA-N 3-[3-[tert-butyl(dimethyl)silyl]oxy-3-phenylpropyl]-4-(3-methoxyphenyl)-1-(4-nitrophenyl)azetidin-2-one Chemical compound COC1=CC=CC(C2N(C(=O)C2CCC(O[Si](C)(C)C(C)(C)C)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 AYZCEVRQUAJWBW-UHFFFAOYSA-N 0.000 description 2
- QRIONSRADSROOL-UHFFFAOYSA-N 5-amino-n-[4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]phenyl]pentanamide Chemical compound C1=CC(OC)=CC=C1C1N(C=2C=CC(NC(=O)CCCCN)=CC=2)C(=O)C1CCC(O)C1=CC=CC=C1 QRIONSRADSROOL-UHFFFAOYSA-N 0.000 description 2
- KAEHHTLMKFAGOE-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[3-(4-azidophenyl)-1-[[5-[4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]anilino]-5-oxopentyl]amino]-1-oxopropan-2-yl]carbamate Chemical compound C1=CC(OC)=CC=C1C1N(C=2C=CC(NC(=O)CCCCNC(=O)C(CC=3C=CC(=CC=3)N=[N+]=[N-])NC(=O)OCC3C4=CC=CC=C4C4=CC=CC=C43)=CC=2)C(=O)C1CCC(O)C1=CC=CC=C1 KAEHHTLMKFAGOE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- BNSTVBLCTRZUDD-KEWYIRBNSA-N N-[(3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide Chemical compound CC(=O)NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BNSTVBLCTRZUDD-KEWYIRBNSA-N 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 2
- VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 2
- 229950005482 pamaqueside Drugs 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
- NDVMCQUOSYOQMZ-UHFFFAOYSA-N 2,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)C(C(N)=O)[Si](C)(C)C NDVMCQUOSYOQMZ-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
- FDDCQWPWXJJNFA-UHFFFAOYSA-N 3-(4-azidophenyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C(=O)O)CC1=CC=C(N=[N+]=[N-])C=C1 FDDCQWPWXJJNFA-UHFFFAOYSA-N 0.000 description 1
- LWPWJQSSRSMWGE-UHFFFAOYSA-N 3-(5-hydroxy-5-phenylpentanoyl)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C=1C=CC=CC=1C(O)CCCC(=O)N(C(OC1)=O)C1C1=CC=CC=C1 LWPWJQSSRSMWGE-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GPUBPSKTFNYPHI-AYGRAXKESA-N 3-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoyl]-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 GPUBPSKTFNYPHI-AYGRAXKESA-N 0.000 description 1
- YPRVALBGAROCLB-UHFFFAOYSA-N 3-[5-[tert-butyl(dimethyl)silyl]oxy-2-[(4-methoxyphenyl)-(4-nitroanilino)methyl]-5-phenylpentanoyl]-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1=CC(OC)=CC=C1C(C(CCC(O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C(=O)N1C(OCC1C=1C=CC=CC=1)=O)NC1=CC=C([N+]([O-])=O)C=C1 YPRVALBGAROCLB-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- ULLSWWGYZWBPHK-UHFFFAOYSA-N 5-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCC(=O)O)C3=CC=CC=C3C2=C1 ULLSWWGYZWBPHK-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- BNSTVBLCTRZUDD-CBQIKETKSA-N N-acetyl-D-glucoseamine Chemical compound CC(=O)N[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BNSTVBLCTRZUDD-CBQIKETKSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940095054 ammoniac Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 238000009838 combustion analysis Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950004437 tiqueside Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02017504 | 2002-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200500053B true ZA200500053B (en) | 2006-07-26 |
Family
ID=31502689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200500053A ZA200500053B (en) | 2002-08-06 | 2005-01-04 | Method for isolating an intestinal cholesterol binding protein |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7435727B2 (es) |
| EP (1) | EP1529061B1 (es) |
| JP (1) | JP4575772B2 (es) |
| KR (1) | KR101095288B1 (es) |
| CN (1) | CN1330667C (es) |
| AT (1) | ATE386053T1 (es) |
| AU (1) | AU2003253341C1 (es) |
| BR (1) | BR0313217A (es) |
| CA (1) | CA2493487C (es) |
| DE (1) | DE60319093T2 (es) |
| HK (1) | HK1082509A1 (es) |
| IL (2) | IL166492A (es) |
| MX (1) | MXPA05001264A (es) |
| NO (2) | NO333437B1 (es) |
| RU (1) | RU2345089C2 (es) |
| WO (1) | WO2004014947A1 (es) |
| ZA (1) | ZA200500053B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US7135556B2 (en) | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| DE602004029715D1 (de) | 2003-12-23 | 2010-12-02 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| JP4590417B2 (ja) | 2004-01-16 | 2010-12-01 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 |
| JP2008546784A (ja) | 2005-06-20 | 2008-12-25 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体 |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| WO2007100807A2 (en) | 2006-02-24 | 2007-09-07 | Schering Corporation | Npc1l1 orthologues |
| AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| CN1869704B (zh) * | 2006-06-14 | 2010-06-30 | 厦门大学 | 快速鉴定与病原菌互作的宿主蛋白的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4710469A (en) * | 1986-05-02 | 1987-12-01 | Merck & Co., Inc. | Novel phosphotyrosyl protein phosphatase |
| ATE140483T1 (de) * | 1988-11-10 | 1996-08-15 | Genetics Inst | Natürlicher killerzellen-stimulationsfaktor |
| ATE209251T1 (de) | 1990-05-16 | 2001-12-15 | Genetics Inst | Knochen- und knorpel-bildung hervorrufende proteine |
| US5264372A (en) * | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| US5518911A (en) * | 1995-01-06 | 1996-05-21 | Onyx Pharmaceuticals, Inc. | Human PAK65 |
| JP3088681B2 (ja) * | 1997-05-22 | 2000-09-18 | 宮城県 | 形質膜局在シアリダーゼ及びそれをコードするｄｎａ |
| US6383734B1 (en) * | 1998-09-30 | 2002-05-07 | Advanced Research And Technology Institute, Inc. | Method to determine inhibition of PAK3 activation of Raf-1 |
| JP2000166545A (ja) * | 1998-12-07 | 2000-06-20 | Snow Brand Milk Prod Co Ltd | 胆汁酸活性化リパーゼ |
| AU3566200A (en) | 1999-04-01 | 2000-10-23 | Astrazeneca Uk Limited | Human signal transduction serine/threonine protein kinase |
| WO2000063703A1 (en) * | 1999-04-16 | 2000-10-26 | Schering Corporation | Use of azetidinone compounds |
| DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
-
2003
- 2003-07-28 CA CA2493487A patent/CA2493487C/en not_active Expired - Fee Related
- 2003-07-28 AU AU2003253341A patent/AU2003253341C1/en not_active Ceased
- 2003-07-28 WO PCT/EP2003/008290 patent/WO2004014947A1/en active IP Right Grant
- 2003-07-28 AT AT03784089T patent/ATE386053T1/de not_active IP Right Cessation
- 2003-07-28 CN CNB038173328A patent/CN1330667C/zh not_active Expired - Fee Related
- 2003-07-28 BR BR0313217-0A patent/BR0313217A/pt not_active IP Right Cessation
- 2003-07-28 RU RU2005106238/13A patent/RU2345089C2/ru not_active IP Right Cessation
- 2003-07-28 EP EP03784089A patent/EP1529061B1/en not_active Expired - Lifetime
- 2003-07-28 JP JP2004526798A patent/JP4575772B2/ja not_active Expired - Fee Related
- 2003-07-28 KR KR1020057002084A patent/KR101095288B1/ko not_active IP Right Cessation
- 2003-07-28 DE DE60319093T patent/DE60319093T2/de not_active Expired - Lifetime
- 2003-07-28 MX MXPA05001264A patent/MXPA05001264A/es active IP Right Grant
- 2003-08-06 US US10/635,008 patent/US7435727B2/en not_active Expired - Fee Related
-
2005
- 2005-01-04 ZA ZA200500053A patent/ZA200500053B/en unknown
- 2005-01-25 IL IL166492A patent/IL166492A/en not_active IP Right Cessation
- 2005-03-04 NO NO20051169A patent/NO333437B1/no not_active IP Right Cessation
-
2006
- 2006-03-13 HK HK06103145A patent/HK1082509A1/xx unknown
-
2007
- 2007-10-16 US US11/872,855 patent/US7786103B2/en not_active Expired - Fee Related
-
2009
- 2009-06-17 IL IL199409A patent/IL199409A/en not_active IP Right Cessation
-
2013
- 2013-01-18 NO NO20130115A patent/NO20130115L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006512054A (ja) | 2006-04-13 |
| US7786103B2 (en) | 2010-08-31 |
| CA2493487A1 (en) | 2004-02-19 |
| CA2493487C (en) | 2013-01-22 |
| NO20051169L (no) | 2005-05-02 |
| IL199409A (en) | 2010-12-30 |
| RU2345089C2 (ru) | 2009-01-27 |
| KR101095288B1 (ko) | 2011-12-16 |
| BR0313217A (pt) | 2005-06-14 |
| ATE386053T1 (de) | 2008-03-15 |
| RU2005106238A (ru) | 2005-08-27 |
| WO2004014947A1 (en) | 2004-02-19 |
| EP1529061A1 (en) | 2005-05-11 |
| KR20060015443A (ko) | 2006-02-17 |
| NO333437B1 (no) | 2013-06-03 |
| US20040126812A1 (en) | 2004-07-01 |
| US20080167451A1 (en) | 2008-07-10 |
| CN1668642A (zh) | 2005-09-14 |
| IL166492A0 (en) | 2006-01-15 |
| AU2003253341C1 (en) | 2009-09-24 |
| US7435727B2 (en) | 2008-10-14 |
| CN1330667C (zh) | 2007-08-08 |
| AU2003253341B2 (en) | 2009-04-23 |
| EP1529061B1 (en) | 2008-02-13 |
| MXPA05001264A (es) | 2005-04-28 |
| DE60319093T2 (de) | 2009-02-05 |
| AU2003253341A1 (en) | 2004-02-25 |
| DE60319093D1 (de) | 2008-03-27 |
| JP4575772B2 (ja) | 2010-11-04 |
| HK1082509A1 (en) | 2006-06-09 |
| IL166492A (en) | 2010-12-30 |
| NO20130115L (no) | 2005-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7786103B2 (en) | Method for isolating an intestinal cholesterol binding protein | |
| US20230364183A1 (en) | Cartilage-homing peptides | |
| US6794359B2 (en) | Vertebrate intestinal protein which absorbs cholesterol, its inhibitors and mehtod of identifying the same | |
| US5045462A (en) | Basic protein called phospholipase A2 isolated from the venom of a snake of the family elapidae and its amino acid sequence | |
| US7094575B2 (en) | Therapeutic and prophylactic agents and methods of using same | |
| Hofsteenge | Ribonuclease inhibitor | |
| JP2008502305A (ja) | 新規なホスフェート結合タンパク質、それを含有する医薬組成物及びその使用 | |
| McGowan et al. | Effects of heparin and other glycosaminoglycans on elastin production by cultured neonatal rat lung fibroblasts | |
| AU6306598A (en) | Peptides for the treatment of systemic lupus erythematosus | |
| JP3728494B2 (ja) | 新規な血清コレステロール低下ペプチド | |
| JPH07503120A (ja) | 細菌からの組換えアポリポタンパク質ｅの精製 | |
| JP2551399B2 (ja) | Ｃ末端アミド化に関与する酵素並びにその製造方法及びその使用 | |
| JP2016516752A (ja) | アテローム性動脈硬化症の治療および予防のための環状ペプチドの使用 | |
| Trifonov et al. | Biological effects of a novel intestinal peptide—inhibiting enterocytogenin on cultured 3T3 mouse fibroblasts and L5178Y mouse lymphoma cells | |
| JPH0291100A (ja) | ヒトホスホリパーゼａ↓２阻害蛋白 | |
| EP0760376A1 (en) | Peptides inhibiting phospholipase c | |
| JPH0469397A (ja) | 新規ペプチド及び用途 | |
| JPH0740935B2 (ja) | Ｃ末端アミド化に関与する酵素ならびにその製造方法および使用 |